His scientific interests lie mostly in Internal medicine, Melanoma, Ipilimumab, Immunology and Surgery. As part of his studies on Internal medicine, he often connects relevant subjects like Oncology. His Melanoma research is multidisciplinary, incorporating elements of Survival rate and Blockade.
In his research on the topic of Ipilimumab, Carboplatin is strongly related with Interim analysis. His work in Immunology addresses issues such as Cancer, which are connected to fields such as Mutation and Gene expression profiling. His Surgery research is multidisciplinary, relying on both Gastroenterology, Placebo and Hazard ratio.
His primary areas of investigation include Internal medicine, Melanoma, Oncology, Ipilimumab and Immunology. His research links Surgery with Internal medicine. His studies in Surgery integrate themes in fields like Placebo, Cohort and Hazard ratio.
His work focuses on many connections between Melanoma and other disciplines, such as Immunotherapy, that overlap with his field of interest in CTLA-4. F. Stephen Hodi has researched Oncology in several fields, including Pembrolizumab, Progressive disease and Advanced melanoma. F. Stephen Hodi combines subjects such as Vemurafenib, Phases of clinical research, Clinical endpoint, Randomized controlled trial and Combination therapy with his study of Ipilimumab.
F. Stephen Hodi mainly focuses on Internal medicine, Melanoma, Oncology, Cancer research and Immunotherapy. Ipilimumab, Nivolumab, Adverse effect and Cancer are the subjects of his Internal medicine studies. His study focuses on the intersection of Nivolumab and fields such as Progressive disease with connections in the field of Lung cancer.
The Melanoma study combines topics in areas such as Clinical trial, Tolerability, Randomized controlled trial, Antigen and Toxicity. His Oncology research incorporates elements of Pembrolizumab, Atezolizumab and Clinical endpoint. His Cancer research research incorporates themes from Cytotoxic T cell, T cell, Immune system and Blockade.
F. Stephen Hodi mainly investigates Internal medicine, Oncology, Melanoma, Cancer research and Immunotherapy. His research integrates issues of Immune checkpoint, Cancer, Nivolumab and Pembrolizumab in his study of Oncology. The concepts of his Melanoma study are interwoven with issues in Interleukin 6, Ipilimumab, Antigen and Atezolizumab.
F. Stephen Hodi performs multidisciplinary study in the fields of Ipilimumab and In patient via his papers. F. Stephen Hodi interconnects Immune checkpoint inhibitors, Immune system, Single agent, Acute-phase protein and Cytotoxic T cell in the investigation of issues within Cancer research. His Immunotherapy research includes elements of Metastatic melanoma, Response criteria, Drug toxicity and Pneumonitis.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.
F. Stephen Hodi;Steven J. O'Day;David F. McDermott;Robert W. Weber.
The New England Journal of Medicine (2010)
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
Suzanne L. Topalian;F. Stephen Hodi;Julie R. Brahmer;Scott N. Gettinger.
The New England Journal of Medicine (2012)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin;Vanna Chiarion-Sileni;Rene Gonzalez;Jean Jacques Grob.
The New England Journal of Medicine (2015)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst;Jean Charles Soria;Marcin Kowanetz;Gregg D. Fine.
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Omid Hamid;Caroline Robert;Adil Daud;F. Stephen Hodi.
The New England Journal of Medicine (2013)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok;Axel Hoos;Steven O'Day;Jeffrey S. Weber.
Clinical Cancer Research (2009)
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Michael A. Postow;Jason Chesney;Anna C. Pavlick;Caroline Robert.
The New England Journal of Medicine (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Jeffrey S Weber;Sandra P D'Angelo;David Minor;F Stephen Hodi.
Lancet Oncology (2015)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian;Mario Sznol;David F. McDermott;Harriet M. Kluger.
Journal of Clinical Oncology (2014)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D. Wolchok;Vanna Chiarion-Sileni;Rene Gonzalez;Piotr Rutkowski.
The New England Journal of Medicine (2017)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: